title: Assessment of human antihuman antibodies to eculizumab after long-term treatment in patients with paroxysmal nocturnal hemoglobinuria.
authors.affiliation: Section of Experimental Haematology, St James's University Hospital, Leeds, United Kingdom.
authors.forename: Peter
authors.initials: P
authors.lastname: Hillmen
authors.affiliation: Department of Hematology, Radboud University Medical Centre, Nijmegen, The Netherlands.
authors.forename: Petra
authors.initials: P
authors.lastname: Muus
authors.affiliation: Department of Clinical Haematology and BMT Service, The Royal Melbourne Hospital, Melbourne, Australia.
authors.forename: Jeffrey
authors.initials: J
authors.lastname: Szer
authors.affiliation: Department of Haematology, St James' Institute of Oncology, Leeds Teaching Hospitals, Leeds, United Kingdom.
authors.forename: Anita
authors.initials: A
authors.lastname: Hill
authors.affiliation: Institute of Transfusion Medicine, University of Ulm, Institute of Clinical Transfusion Medicine and Immunogenetics Ulm, German Red Cross Blood Transfusion Service Baden-Württemberg-Hessen, and University Hospital Ulm, Ulm, Germany.
authors.forename: Britta
authors.initials: B
authors.lastname: Höchsmann
authors.affiliation: King's College Hospital, Hill, Denmark, London, United Kingdom.
authors.forename: Austin
authors.initials: A
authors.lastname: Kulasekararaj
authors.affiliation: Dipartimento Di Medicina Clinica E Chirurgia Dell' Università Degli Studi Di Napoli Federico II, Napoli, Italy.
authors.forename: Antonio M
authors.initials: AM
authors.lastname: Risitano
authors.affiliation: Hematology Department, Cliniques Universitaires UCL Saint-Luc, Brussels, Belgium.
authors.forename: Eric
authors.initials: E
authors.lastname: Van Den Neste
authors.affiliation: Hematology Department, University Hospital of Umea, Umea, Sweden.
authors.forename: Maria
authors.initials: M
authors.lastname: Liljeholm
authors.affiliation: New England Cancer Specialists, Scarborough, Maine.
authors.forename: Kurt S
authors.initials: KS
authors.lastname: Ebrahim
authors.affiliation: Alexion Pharmaceuticals, Inc, Cheshire, Connecticut.
authors.forename: Camille L
authors.initials: CL
authors.lastname: Bedrosian
authors.affiliation: Alexion Pharmaceuticals, Inc, Cheshire, Connecticut.
authors.forename: Xiang
authors.initials: X
authors.lastname: Gao
authors.affiliation: Alexion Pharmaceuticals, Inc, Cheshire, Connecticut.
authors.forename: Donna
authors.initials: D
authors.lastname: Ames
authors.affiliation: AP-HP Hematology Hospital Saint Louis, Paris, France.
authors.forename: Gérard
authors.initials: G
authors.lastname: Socié
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D057134:Antibodies, Neutralizing / Q000097:blood*; D003182:Complement C5 / Q000037:antagonists & inhibitors; D051056:Complement Inactivating Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D005260:Female; D006457:Hemoglobinuria, Paroxysmal / Q000097:blood / Q000188:drug therapy* / Q000276:immunology; D006461:Hemolysis / Q000187:drug effects* / Q000276:immunology; D006801:Humans; D008297:Male; D008875:Middle Aged; D013997:Time Factors
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D057134:Antibodies, Neutralizing; D003182:Complement C5; D051056:Complement Inactivating Agents; C481642:eculizumab